European Commission Approves Astellas’ XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation



Approval follows accelerated assessment, orphan designation by European Medicines Agency

TOKYO, Oct. 25, 2019 — (Healthcare Sales &Marketing Network) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) … Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia

Source: HSMN NewsFeedCategory: Pharmaceuticals Source Type: news

Related Links:

Conditions:   AML/MDS;   CMML;   Relapse;   Refractory Acute Lymphoblastic Leukemia;   Relapse Leukemia;   Relapsed Adult AML Intervention:   Drug: LP-108 Sponsor:   Newave Pharmaceutical Inc Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
Oncol Rep. 2019 Oct 15;:
Authors: Yu G, Yin C, Wu F, Jiang L, Zheng Z, Xu D, Zhou J, Jiang X, Liu Q, Meng F
Gene mutations play an important role in the development and progression of AML1‑ETO‑positive acute myeloid leukemia (AE‑AML). Nevertheless, the gene mutation profile in this subtype of leukemia remains unclear. In addition, the clinical and prognostic effects of different mutant genes may be underestimated. In the present study, gene sequencing was c…

Source: Oncology ReportsCategory: Cancer & Oncology Tags: Oncol Rep Source Type: research

Authors: Li Y, Zhang G, Wu B, Yang W, Liu Z
Chemotherapy resistance is still a primary clinical obstacle to the successful treatment of acute myeloid leukemia (AML). The underlying mechanisms of drug resistance are complicated and have not been fully understood. Here, we found that miR-199a-5p levels were significantly reduced in refractory/relapsed AML patients compared to those who achieved complete remission after chemotherapy. Consistently, miR-199a-5p was markedly decreased in Adriamycin-resistant AML K562/ADM cells in contrast with Adriamycin-sensitive K562 cells, and its decrement dramatically corre…

Source: Journal of OncologyCategory: Cancer & Oncology Tags: J Oncol Source Type: research

CONCLUSIONS: High expression level of ACOT7 indicates unfavorable outcome in AML patients. Allo-HSCT could not overcome the unfavorable effect of ACOT7 in these patients.
PMID: 31640082 [PubMed – as supplied by publisher]

Source: Cancer BiomarkersCategory: Cancer & Oncology Tags: Cancer Biomark Source Type: research

Contributors : Xiaoxuan Zhuang ; Daniel P Veltri ; Eric O LongSeries Type : OtherOrganism : Homo sapiensThe anti-leukemia activity of NK cells helps to prevent relapse during hematopoietic stem cell transplantation in leukemia patients. However, the factors that determine sensitivity or resistance of leukemia cells in the context of NK-mediated cytotoxicity are not well established. Here we performed a genome-wide CRIPSR screen in the human chronic-myelogenous-leukemia (CML) cell line K562 to identify genes that regulate vulnerability of leukemia cells to killing by primary human NK cells. Distribution of guide RNAs (gRNAs…

Contributors : Chujiao Hu ; Lei Tang ; Hao ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia. By screening dozens of reported natural compounds using both wild-type and mutant IDH1 enzymatic assays, we discovered Licochalcone A is a selective inhibitor to the R132C-mutant IDH1 with an IC50 value of 5.176 μM, and inhibits the proliferation of HT1080 cells with an IC50 value of 10.75 μM. Suggested by the molecular docking resu…

Source: GEO: Gene Expression OmnibusCategory: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Conclusion: Different molecular and clinical characteristics existed between patients with DNMT3A variant subtypes. The distinct microRNA expression pattern for DNMT3A R882 AML patients might not only act as markers to predict disease prognosis, but also could be further investigated to develop novel therapeutic targets for patients with DNMT3A mutations.

Oncogene, Published online: 24 October 2019; doi:10.1038/s41388-019-1069-yDisruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells

Source: OncogeneCategory: Cancer & Oncology Authors: Source Type: research

This study aimed to elucidate the value of immune/stromal cell-associated genes for AML prognosis by integrated bioinformatics analysis. We obtained expression profiles from The Cancer Genome Atlas (TCGA) database and used the ESTIMATE algorithm to calculate immune scores and stromal scores; we then identified differentially expressed genes (DEGs) based on these scores. Overall survival analysis was applied to reveal common DEGs of prognostic value. Subsequently, we conducted a functional enrichment analysis, generated a protein –protein interaction (PPI) network and performed an interrelation analysis of immune syst…

Personalized Medicine, Ahead of Print.

Source: Future Medicine: Personalized MedicineCategory: Genetics & Stem Cells Authors: Source Type: research


Source link